These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9827615)

  • 21. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
    Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
    Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unified Huntington's disease rating scale for advanced patients: validation and follow-up study.
    Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
    Mov Disord; 2013 Oct; 28(12):1717-23. PubMed ID: 24166899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life in Huntington's disease: Which factors matter most?
    Ho AK; Gilbert AS; Mason SL; Goodman AO; Barker RA
    Mov Disord; 2009 Mar; 24(4):574-8. PubMed ID: 19097181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of coenzyme Q10 tolerability in Huntington's disease.
    Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I
    Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of psychopathology in Huntington's disease: the critical role of caregivers.
    van Duijn E; Giltay EJ; Zitman FG; Roos RA; van der Mast RC
    J Nerv Ment Dis; 2010 May; 198(5):329-33. PubMed ID: 20458193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up.
    van Vugt JP; Piet KK; Vink LJ; Siesling S; Zwinderman AH; Middelkoop HA; Roos RA
    Mov Disord; 2004 Mar; 19(3):285-97. PubMed ID: 15022182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postural deficits in Huntington's disease when performing motor skills involved in daily living.
    Panzera R; Salomonczyk D; Pirogovosky E; Simmons R; Goldstein J; Corey-Bloom J; Gilbert PE
    Gait Posture; 2011 Mar; 33(3):457-61. PubMed ID: 21256027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rate of functional decline in Huntington's disease. Huntington Study Group.
    Marder K; Zhao H; Myers RH; Cudkowicz M; Kayson E; Kieburtz K; Orme C; Paulsen J; Penney JB; Siemers E; Shoulson I
    Neurology; 2000 Jan; 54(2):452-8. PubMed ID: 10668713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors contributing to institutionalization in patients with Huntington's disease.
    Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
    Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Internal consistency of a Brazilian version of the unified Huntington's disease rating scale.
    Tumas V; Camargos ST; Jalali PS; Galesso Ade P; Marques W
    Arq Neuropsiquiatr; 2004 Dec; 62(4):977-82. PubMed ID: 15608955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor cortical excitability studied with repetitive transcranial magnetic stimulation in patients with Huntington's disease.
    Lorenzano C; Dinapoli L; Gilio F; Suppa A; Bagnato S; Currà A; Inghilleri M; Berardelli A
    Clin Neurophysiol; 2006 Aug; 117(8):1677-81. PubMed ID: 16793338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease.
    Maroof DA; Gross AL; Brandt J
    J Clin Exp Neuropsychol; 2011 Oct; 33(8):901-9. PubMed ID: 21644140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.
    Kingma EM; van Duijn E; Timman R; van der Mast RC; Roos RA
    Gen Hosp Psychiatry; 2008; 30(2):155-61. PubMed ID: 18291297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Executive dysfunction in Huntington's disease].
    Redondo Vergé L; Brown RG; Chacón J
    Rev Neurol; 2001 May 16-31; 32(10):923-9. PubMed ID: 11424047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.
    Reedeker N; Van Der Mast RC; Giltay EJ; Van Duijn E; Roos RA
    Mov Disord; 2010 Aug; 25(11):1612-8. PubMed ID: 20629165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of intensive neurorehabilitation in patients with Huntington's disease.
    Ciancarelli I; Tozzi Ciancarelli MG; Carolei A
    Eur J Phys Rehabil Med; 2013 Apr; 49(2):189-95. PubMed ID: 23480977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.